# Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers

> **NCT04943445** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Latin American Cooperative Oncology Group** · enrollment: 43 (actual)

## Conditions studied

- Squamous Cell Carcinoma of Larynx

## Interventions

- **DRUG:** carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles
- **RADIATION:** Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.
- **DRUG:** Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.

## Key facts

- **NCT ID:** NCT04943445
- **Lead sponsor:** Latin American Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-22
- **Primary completion:** 2025-10-16
- **Final completion:** 2025-10-16
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04943445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04943445, "Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04943445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*